Abstract
In 82 patients with stage II or III malignant tumors of the head and neck, the cumulative survival rate was compared between 55 treated with and 27 not treated with OK-432. The annual survival rate was consistently higher in those treated than in those not treated with the agent; a significant difference was observed after 3 years and a slight different after 5 years.Intracutaneous administration of OK-432 had no effects on the cumulative survival rate, presumably because activation of pyrimidine fluoride compounds was unaffected.Of 57 parameters tested, we describe 9 immunological and biochemical parameters used in our hospital that indicate the onset and prognosis of malignant tumors of the head and neck. These parameters were:aspirin esterase, fibrinogen, a2-globulin, and cholinesterase levels; lymphocyte count, Su-Ps skin test, and PPD skin test; lymphocytes blastgenesis to PHA; and iron level.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
